D-1055-2020 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-1055-2020 was initiated by Lupin Pharmaceuticals Inc. on Mar 9, 2020 and is designated Class III. Reason for recall: Failed Content Uniformity Specifications: Out Of Specification test results observed for content and blend uniformity. The recall status is terminated (terminated May 25, 2021). Affected quantity: 1,712 cartons.

Recall details

Product Type
Drugs
Report Date
Mar 18, 2020
Initiation Date
Mar 9, 2020
Termination Date
May 25, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,712 cartons

Product description

Bekyree (desogestrel and ethinyl estradiol tablets USP, 0.15 mg/0.02 mg and ethinyl estradiol tablets USP, 0.01 mg), packaged in 1 Wallet of 28 Tablets (NDC 68180-879-11), 3 Wallets of 28 Tablets Each per carton (NDC 68180-879-13), Rx Only, Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Pithampur (M.P.) - 454775, INDIA.

Reason for recall

Failed Content Uniformity Specifications: Out Of Specification test results observed for content and blend uniformity.

Distribution pattern

Nationwide in the USA and Puerto Rico.

Code information

Lot #: L800915, Exp July 2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1055-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1055-2020. Report a data issue: hello@regdatalab.com.